Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243763
Status:
TERMINATED
Last Update Posted:
2009-11-23
First Post:
2005-10-21
Brief Title:
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Phase 1 Dose Escalating Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to determine the maximum tolerated dose MTD dose limiting toxicity DLT and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma MM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None